Skip to main content Accessibility help
  • Print publication year: 2008
  • Online publication date: August 2009

5 - Management of glycaemia by oral hypoglycaemic agents

Related content

Powered by UNSILO
Dormandy, J. A., Charbonnel, B., Eckland, D. J. al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–89.
Higgs, E. R., and Krentz, A. J. (2004) Association of British Clinical Diabetologists position statement on glitazones. Practical Diabetes International 21: 1–3.
Holman, R. R., Cull, C. A. and Turner, R. C. (1999) A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22: 960–4.
Khan, S. E., Haffner, S. M., Heise, M. al. (2006) Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. New England Journal of Medicine 355: 2427–43.
Nathan, D. M., Buse, J. B., Davidson, M. al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 49: 1711–21.
Nissan, S. E., and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356: 2457–71.
,Nutrition Committee of the Diabetes Care Advisory Committee of Diabetes UK (2003) The implementation of nutritional advice for people with diabetes. Diabetic Medicine 20: 786–807.
Schwartz, A. V., and Sellmeyer, D. E. (2007) Thiazolidinedione therapy gets complicated. Is bone loss the price of improved insulin resistance?Diabetes Care 30: 1670–71.
Stratton, I. M., Adler, A. I., Neil, H. al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321: 405–12.
,UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with diabetes (UKPDS 34). Lancet 352: 854–65.